Thursday 15 October 2026 Export CGEN’s income statement to Excel — free account

Compugen Ltd.

Compugen Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $72.8 million, up 161.1% from fiscal 2024. In the quarter to June 2026, revenue grew 107.0%, EPS grew 12.5% and free cash flow fell 155.4%, each against the same quarter a year earlier.

2.08 0.08 +4.00%

Follow CGEN

Alert me

Market cap: $187.6M
P/E: 5.5×
Fwd P/E: −7.2×
Dividend yield: —
F-score: 7/9
Altman Z: −0.37
Beneish M: −1.59
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.12

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	1	8	—	—	1	—	—	—

Insider Ownership 0.29%

Capital & Financial Ratios $m

Market Cap 187.56

Revenue 74.00

Net Income 35.19

Free Cash Flow 40.04

Net Debt (125.30)

Current Ratio 5.72

Debt/Equity 0.00

P/E ratio 5.47

Fwd P/E (7.24)

P/S ratio 2.66

P/B ratio 2.22

Past 5Y EPS Growth —

This Y EPS Growth (173.68%)

Next Y EPS Growth 1.43%

Next Y revenue growth (87.30%)

Next 5Y EPS Growth 1.27%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 2.10%

10-year low 10-year high

P/B against its own 10 years 24.15%

10-year low 10-year high

EV/Sales against its own 10 years 8.58%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	51	103	146	125
Receivables	64	3	2	4
Inventory	—	—	—	—
Other	—	—	—	—
	115	106	148	129

	2023	2024	2025	Q'26
Payables	4	2	2	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	26	20	23	23

Compound Annual Growth %

	10y	5y	3y
Sales	—	105.20%	113.28%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	1.34%	(3.02%)	9.77%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	2	3	—	—	—
’25	2	1	2	67	73
’24	3	7	17	1	28
’23	—	—	—	—	33
’22	—	—	—	8	8
’21	—	—	6	—	6
’20	—	—	—	2	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	(22)	—	—	—
’25	—	(19)	—	32	32
’24	—	40	—	50	50
’23	—	—	—	—	(36)
’22	—	—	—	—	(34)
’21	—	—	—	—	(23)
’20	—	—	—	—	(28)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	(22)	—	—	—
’25	—	(19)	—	31	31
’24	—	40	—	49	49
’23	—	0	—	0	(36)
’22	—	0	—	0	(35)
’21	—	0	—	0	(23)
’20	—	0	—	0	(28)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.08)	(0.07)	—	—	—
’25	(0.08)	(0.08)	(0.07)	0.60	0.38
’24	(0.08)	(0.02)	0.01	(0.07)	(0.16)
’23	(0.11)	(0.11)	(0.11)	0.11	(0.21)
’22	(0.11)	(0.11)	(0.14)	(0.04)	(0.39)
’21	(0.12)	(0.11)	(0.07)	(0.10)	(0.41)
’20	(0.10)	(0.08)	(0.09)	(0.10)	(0.37)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	4.32	2.25	2.00	2.17	5.62	3.68	0.51	0.53	1.35	1.13	Analyst estimates 2026–2028 Powerpack
	High	7.57	5.40	5.00	6.32	19.90	14.30	4.64	2.46	3.03	2.66
People
People	Employees	98	101	89	61	68	73	69	68	74	75
	Revenue/emp, $m	0.01	0.00	0.20	0.00	0.03	0.08	0.11	0.49	0.38	0.97
Income, $m
Income, $m	Revenue	1	—	18	—	2	6	8	33	28	73
	Gross margin, %	68.68	0.00	94.19	0.00	97.00	88.67	87.00	94.01	71.54	87.29
	EBT	(31)	(37)	(23)	(28)	(30)	(34)	(34)	(10)	(10)	35
	EBT margin, %	(4,422.19)	0.00	(126.96)	0.00	(1,484.90)	(570.05)	(448.48)	(29.24)	(34.84)	48.65
	Net income	(32)	(37)	(23)	(27)	(30)	(34)	(34)	(19)	(14)	35
	Depreciation	1	2	1	1	1	0	0	0	(1)	0
Per share, $
Per share, $	Revenue	0.01	0.00	0.32	0.00	0.03	0.07	0.09	0.38	0.31	0.78
	Earnings	(0.62)	(0.72)	(0.41)	(0.43)	(0.37)	(0.41)	(0.39)	(0.21)	(0.16)	0.38
	Cash flow	(0.39)	(0.60)	(0.24)	(0.44)	(0.36)	(0.27)	(0.39)	(0.41)	0.55	0.34
	Capex	(0.05)	(0.01)	0.00	0.00	0.00	0.00	(0.01)	0.00	0.00	0.00
	Free cash flow	(0.44)	(0.61)	(0.24)	(0.43)	(0.36)	(0.27)	(0.40)	(0.41)	0.55	0.34
	Book value	1.25	0.57	0.67	0.60	1.51	1.27	0.90	0.75	0.61	1.10
	Shares, m	51	51	55	64	80	84	87	88	90	93
Valuation, ×
Valuation, ×	P/E	0.00	—	0.00	—	0.00	0.00	0.00	0.00	0.00	4.14
	P/S	364.28	—	6.72	—	48.68	22.92	3.96	11.31	4.92	1.96
	P/B	4.08	—	3.22	—	8.05	3.39	0.79	2.67	2.49	1.39
	EV/Sales	277.86	—	4.16	—	42.39	15.46	(1.44)	8.01	1.21	(0.04)
	EV/FCF	(3.32)	—	(1.10)	—	(10.00)	(3.17)	0.24	(1.13)	0.53	(0.03)
Cash, $m
Cash, $m	Operating cash flow	(20)	(31)	(13)	(28)	(28)	(23)	(34)	(36)	50	32
	Capex	(3)	0	0	0	0	0	0	0	0	0
	Free cash flow	(22)	(31)	(13)	(28)	(28)	(23)	(35)	(36)	49	31
Balance, $m
Balance, $m	Working capital	58	25	37	38	119	106	74	88	86	125
	Total debt	—	—	—	4	3	3	2	—	—	—
	Net debt	(62)	(30)	(46)	(44)	(124)	(118)	(84)	(51)	(103)	(146)
	Shareholders’ equity	64	29	37	38	120	107	78	66	55	103
Returns, %
Returns, %	ROA	(36.97)	(67.46)	(49.17)	(51.12)	(30.92)	(25.29)	(29.77)	(17.40)	(12.04)	26.03
	ROIC	(1,022.31)	0.00	0.00	0.00	0.00	0.00	0.00	(55.97)	0.00	0.00
	ROE	(41.07)	(79.87)	(67.93)	(72.35)	(37.57)	(30.20)	(36.55)	(26.19)	(23.63)	44.84

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LYEL Lyell Immunopharma, Inc.	$195.8M	— (loss-making)	— (loss-making)	−50.00% (below 0%: shrinking)	n/m	+1.31% (above 0%: growing)	100.00%	(1,183,425.00%)	Compare
RNAC Cartesian Therapeutics, Inc.	$191.8M	— (loss-making)	— (loss-making)	−92.91% (below 0%: shrinking)	−7.84% (below 0%: shrinking)	−6.15% (below 0%: shrinking)	100.00%	0.00%	Compare
ACOG Alpha Cognition Inc.	$191.7M	— (loss-making)	—	+267.56% (above 0%: growing)	n/m	−109.25% (below 0%: shrinking)	94.80%	(127.29%)	Compare
IVVD Invivyd, Inc.	$190.4M	— (loss-making)	— (loss-making)	+21.20% (above 0%: growing)	n/m	−226.89% (below 0%: shrinking)	91.09%	(320.76%)	Compare
ELDN Eledon Pharmaceuticals, Inc.	$190.2M	— (loss-making)	—	—	n/m	−28.02% (below 0%: shrinking)	0.00%	0.00%	Compare
CGEN Compugen Ltd.	$187.6M	5.5×	— (loss-making)	+107.00% (above 0%: growing)	n/m	−155.42% (below 0%: shrinking)	(3.54%)	(339.62%)
UPB Upstream Bio, Inc.	$187.3M	— (loss-making)	— (loss-making)	−17.50% (below 0%: shrinking)	n/m	+9.33% (above 0%: growing)	100.00%	(5,480.98%)	Compare
SION Sionna Therapeutics, Inc.	$185.0M	— (loss-making)	—	—	n/m	−22.40% (below 0%: shrinking)	—	0.00%	Compare
BCYC Bicycle Therapeutics PLC Sponsored ADR	$182.9M	— (loss-making)	— (loss-making)	−78.46% (below 0%: shrinking)	n/m	+31.95% (above 0%: growing)	100.00%	(8,673.93%)	Compare
Median of peers	$190.3M	—	—	−33.75%	—	−14.27%	100.00%	(224.02%)

All 614 Biotechnology stocks →

Compugen Ltd. (CGEN) key facts

Strength: Compugen Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $72.8 million, up 161.1% from fiscal 2024.
Compugen Ltd. (CGEN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 15, 2026, CGEN traded at $2.08, a market capitalization of $187.6 million.
Return on equity was 44.8% and debt-to-equity 0.00.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is −0.37 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.